

**21st Annual John Goldman Conference on
Chronic Myeloid Leukemia: Biology and Therapy
Bordeaux, France
September 12-15, 2019**

These abstracts are presented in alphabetical order according to the name of the first author.

CLINICAL POSTERS

- POSTER 19: Implementation of a Treatment-Free Remission Program (TFR) in Patients with Chronic Myeloid Leukemia (CML) at an University Hospital in Colombia
Virginia Abello, Claudia Casas, Daniel Espinosa, Guillermo León, Miguel Alejandro Palacios, María Helena Solano
- POSTER 20: The Impact of Health Care Insurance Difference on Outcomes of Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI)
Virginia Abello, Claudia Casas, Daniel Espinosa, Guillermo León Basantes, María Helena Solano
- POSTER 21: Comparison of Digital Droplet Polymerase Chain Reaction (ddPCR) Technology to Real Time Quantitative PCR (RT-qPCR) for Detection of BCR-ABL p210 Transcript upon Tyrosine Kinase Inhibitor Discontinuation in Patients with CP-CML
Hannah Asghari, Chetasi Talati, Alex Achille, John Powers, Eva Sahakian, Onyee Chan, Leidy Isenalumhe, Lisa Nodzon, Kendra Sweet, Javier Pinilla-Ibarz
- POSTER 22: Vaccination with Live Attenuated Virus Vaccines in Three Pediatric Patients with CML While on Imatinib Treatment.
Claudia Bettoni Da Cunha-Riehm, Verena Hildebrand, Markus Metzler, Meinolf Suttorp
- POSTER 23: Analysis of the T-Cell repertoire by Next-Generation Sequencing to predict successful Treatment-Free Remission (TFR) in CML
Lambert Busque, Manuel Buscarlet, Ann Brasey, Geneviève Huynh-Trudeau, Sami Ayashi, Béatrice Turcq, Dennis Kim, François-Xavier Mahon
- POSTER 24: Visual Impairment in CML As a Shared Adverse Event across TKI Drugs
Maria Couto, Isabel Oliveira, José Mariz
- POSTER 25: Epidemiological Modeling of the Repartition of the Main Therapeutic Pathways in Chronic Myeloid Leukemia: Application to the French Cohort
Marc Delord, Jonathan Finzi, Philippe Rousselot
- POSTER 26: Blastic Phase CML Initially Presented As Multiple Chloroma Running Title; Successful Long Term Remission with Dasatinib
Young Rok Do, EunHee Jung, Mi Wha Heo, Jin Young Kim, Ji Woon Yae

- POSTER 27: Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis Based on European Leukemianet Recommendations in Chronic Myeloid Leukemia
Young Rok Do, Soo-Hyun Kim, Soo-Young Choi, Dong-Wook Kim, Dae Young Zang
- POSTER 28: Comparison of the Efficacy of Chinese Generic Imatinib with Branded Imatinib As Frontline Therapy in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian Jiang
- POSTER 29: Primary Therapy and Relative Survival Among Elderly Patients with Chronic Myeloid Leukemia: A Population-Based Registry Study in the Netherlands, 1989-2016.
Geneviève Ector, Otto Visser, Peter E. Westerweel, Jeroen J. Janssen, Nicole Blijlevens, Avinash Dinmohamed
- POSTER 30: Imatinib Discontinuation in Asian CML Patients with Sustained Deep Molecular Remission
Manjia Fu, Raudhatul Nur Shaqirin Bte Ghazali, Yeow Tee Goh, Hein Than, Charles Chuah
- POSTER 31: Do We Know the Best Duration of Tyrosine Kinase-Inhibitor Therapy and/or Deep Molecular Remission to Achieve Therapy-Free Remission?
Robert Peter Gale, Mei-Jie Zhang
- POSTER 32: Atypical e1a2 p190 BCR-ABL1 Fusion Transcript in High Risk Chronic Myeloid Leukemia (CML) Subset: Sustained Hematological and Molecular Responses with an Optimal Clinical and Molecular Follow-up.
Isabel Giere, Mariana Debus, María José Mela Osorio, Miguel A. Pavlovsky, Isolda Fernandez, Beatriz Moiraghi, Maria Teresa Cuello, Carolina Pavlovsky
- POSTER 33: Characterizing Frailty in Patients with Chronic Myeloid Leukemia
Christopher Hillis, Sarah Karampatos, Darryl Leong, Deborah Siegal, Nicholas Jackson Chornenki
- POSTER 34: Comprehensive Analysis on the Hematological Parameter Changes after TKI Discontinuation for the Treatment-Free Remission Attempt
Dennis Dong Hwan Kim
- POSTER 35: BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after after Imatinib Discontinuation As a Predictive for Successful TKI Discontinuation for Treatment-Free Remission
Dennis Dong Hwan Kim
- POSTER 36: Arterial Vascular Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients
Jee Hyun Kong, Tae-Hwa Go, Hohyung Nam, Seung Taek Lim, Shin Young Hyun, Kwang Yong Shim, Jong In Lee

- POSTER 37: Prevalence of Normal Population Harboursing BCR-ABL1 Fusion Gene in Southern Sarawak, Borneo Island
Jew Win Kuan, Anselm Ting Su, Siow Phing Tay, Isabel Lim Fong, Sho Kubota, Lela Su'ut, Motomi Osato, Goro Sashida
- POSTER 38: Cognitive Impairment in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor-Therapy
Zongru Li, Qian Jiang
- POSTER 39: Novel Score Based Decision Approach In The Chronic Myeloid Leukemia Patients After The Acute Toxic Imatinib-Induced Liver Injury
Nataliia Lopina, Iryna Dmytrenko, Dmytro Hamov, Dmytro Lopin, Larysa Zhuravlyova, Iryna Dyagil
- POSTER 40: Microrna-21 over-Expression As Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients
Mirza Masroor Ali Beg, Sameer Ahmad Guru, Saleh Mohammed Abdullah, Aliya Rizvi, Alpana Saxena
- POSTER 41: Analysis of Cardiovascular Risk Factors and Cardiovascular Adverse Events in Patients Treated with Ponatinib in "Real-Life": Argentine Experience
María José Mela Osorio, Beatriz Moiraghi, Miguel A. Pavlovsky, Isolda Fernandez, Ana Varela, Federico Sackmann, Victoria Osycka, Isabel Giere, Angela Moyano, Leandro Rodriguez, Maximiliano Riddick, Carolina Pavlovsky
- POSTER 42: Clinical, Biochemical Characteristics and Risk Groups of Chronic Myeloid Leukemia in Children
Quoc Thanh Nguyen
- POSTER 43: Ponatinib Long-Term Follow-up of Efficacy and Safety in CP-CML Patients in Real World Settings in France: The Post-PACE Study
Franck E. Nicolini, Delphine Rea, Valérie Coiteux, Agnès Guerci-Bresler, Françoise Huguet, Jean-Michel Karsenti, Laurence Legros, Philippe Rousselot, Gabriel Etienne
- POSTER 44: Prospective Assessment of Dasatinib Management in CP-CML Patients in a Real Life Setting: Interim Analysis of Dasarealise Study.
Franck E. Nicolini, Agnès Guerci-Bresler, MD, PhD, Hyacinthe Johnson-Ansah, Françoise Huguet, Gabriel Etienne, Viviane Dubruille, Omar Benbrahim, Laurence Legros, Fabrice Larosa, Véronique Moreau-Mallet, François-Xavier Mahon
- POSTER 45: Treatment Free Remission of Chronic Myeloid Leukemia in Real-World Practice
Sungwoo Park, Jee Hyun Kong, Eun-Ji Choi, Chul Won Jung, Duk-yeon Cho, Hyewon Lee, Hawk Kim

- POSTER 46: Prospective Assessment of Cardiovascular Events in CML Patients Treated with Nilotinib
Tamires Prates Lang, Marcia Torresan Delamain, Gislaine Oliveira Duarte, Fabio Menezes, Carmino Antonio de Souza, Erich Vinicius de Paula, Katia B B Pagnano
- POSTER 47: Do Persons with Chronic Myeloid Leukaemia Really Have Normal or Better Survival Than Controls?
Tomas Radivoyevitch, Davis Weaver, Brian Hobbs, Jarislaw Maciejewski, Rüdiger Hehlmann, Robert Peter Gale
- POSTER 48: Anxiety and Depression Are Associated with Worse Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia
Dayu Shi, Qian Jiang
- POSTER 49: Variables Associated with BCR-ABL Kinase Domain Mutation in TKI-Resistant Patients with Chronic Myeloid Leukemia
Dayu Shi, Yazhen Qin, Qian Jiang
- POSTER 50: Use of Droplet Digital Polymerase Chain Reaction for Detection of Minimal Residual Disease in Chronic Myelogenous Leukemia: A Prospective, Multi-Institutional Study.
Sang Kyun Sohn, Hyungkyung Park, Inho Kim
- POSTER 51: Dasatinib-Induced Pulmonary Hypertension in Two Patients with Diagnosis of Chronic Myeloid Leukemia
Claudia Sossa, Sara Jimenez, Claudia Chalela, Julian Baez, Manuel Rosales, Angela Peña, Luis Salazar
- POSTER 52: Prognostic Relevance of Sustained Serial Resistance in Chronic Myeloid Leukemia: Real-World Evidence from the Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Quebec Research Group
Natasha Szuber, Michael Harnois, Michel-Olivier Gratton, Sarit Assouline, Pierre Laneuville, Harold Olney, Robert Delage, Luigina Mollica, Lambert Busque
- POSTER 53: The Second-Generation Tyrosine Kinase Inhibitors Can Overcome Poor Prognosis of Additional Chromosomal Abnormalities in Patients with Chronic Myeloid Leukemia According to the New Target Observational Study 1
Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Itaru Matsumura
- POSTER 54: Measurement of Imatinib and Bosutinib Concentrations in Plasma and Scalp Hair in Patients with Chronic Myeloid Leukemia
Srinivas K. Tantravahi, Anthony D. Pomicter, Phillip M. Clair, David J. Anderson, Diana Wilkins, Thomas O'Hare, Michael W. Deininger
- POSTER 55: Inhibition of Leukotriene Signaling in CML Provides an Additional Target for Therapy
Elham Yektaei-Karin, Ana Zovko, Daniel Salamon, Jonas Wallvik, Leif Stenke

- POSTER 56: Comparison of Responses and Outcomes between Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated Phase and Those in the Chronic Phase Receiving Tyrosine Kinase Inhibitors
Lu Yu, Yazhen Qin, Hongxia Shi, Yueyun Lai, Xiaojun Huang, Qian Jiang
- POSTER 57: Socio-Demographics on Outcomes in Adults with Newly Diagnosed Chronic Myeloid Leukemia Receiving Frontline Tyrosine Kinase Inhibitor Therapy
Lu Yu, Yazhen Qin, Hongxia Shi, Yueyun Lai, Xiaojun Huang, Qian Jiang
- POSTER 58: Coexistence of Lymphoid Neoplasms with Chronic Myeloid Leukemia.
Rocío Zapata Bautista, Susana Ramírez García, María Solé Rodríguez, Juan Nicolás Rodríguez Rodríguez, Antonio José Palma Vallellano, Karoll Gómez Correcha, Encarnación Gil Espárraga, Juan Francisco Domínguez Rodríguez, María Antonia Ruíz Cobo, Bianca Díaz Roldan, Francisco Fernández Moreno, Pilar Velarde López de Ayala